Adenosine Receptors Profile in Fibromuscular Dysplasia

Claire Guiol1, Sarah El Harake2, Julien Fromonot1,3

  • 1Centre for Cardiovascular Research and Nutrition, C2VN, INSERM, INRAE, Aix Marseille University, 13000 Marseille, France.

Biomedicines
|November 11, 2022
PubMed

Insights

Fibromuscular dysplasia (FMD) diagnosis may be improved by measuring adenosine blood levels (ABL) and adenosine A2B receptor (A2BR) production. Elevated ABL and A2BR overproduction were observed in FMD patients, suggesting their potential as diagnostic biomarkers.

Area of Science:

  • Vascular Biology
  • Biochemistry
  • Medical Diagnostics

Background:

  • Fibromuscular dysplasia (FMD) is a non-inflammatory vascular disease causing hypertension in young individuals.
  • Current diagnosis relies on catheter-angiography, often leading to delays.
  • Adenosine and its receptors are potential factors in FMD pathophysiology.

Purpose of the Study:

  • To investigate the association between adenosine blood levels (ABL) and adenosine receptor production with FMD.
  • To explore the potential of ABL and adenosine receptor A2BR as diagnostic biomarkers for FMD.

Main Methods:

  • Evaluated adenosine A1, A2A, and A2B receptor production using Western blot in 67 FMD patients and 40 controls.
  • Measured adenosine blood levels (ABL) via liquid chromatography-mass spectrometry.
  • Assessed A2BR production cutoff for diagnostic sensitivity and specificity.

Main Results:

  • Adenosine blood levels (ABL) were significantly higher in FMD patients (+180%) compared to controls.
  • Overproduction of adenosine A2B receptors (A2BR) was found in FMD patients (+65%).
  • A2BR production with a cutoff of 1.3 arbitrary units demonstrated good diagnostic sensitivity and specificity.

Conclusions:

  • Elevated ABL and A2BR overproduction are associated with FMD.
  • Measuring A2BR production on monocytes and ABL may aid in FMD diagnosis, particularly in complex cases.
  • These biomarkers offer a potential adjunctive diagnostic tool for FMD.

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.7K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.9K
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.8K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.6K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
673
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
919